Author: admin

DelveInsight’s “Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Neuroendocrine Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Neuroendocrine Tumor market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuroendocrine Tumor Market Insights

Neuroendocrine Tumor Overview

According to the Neuroendocrine Tumor Patient Foundation (n.d.)- “Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor)”.

Neuroendocrine tumors originate from enterochromaffin cells that are part of the neuroendocrine system of the bronchial and gastrointestinal tract. Based on the anatomic site of origin, NETs originating from gastric, duodenal, pancreatic, small intestine, appendiceal, colon, and rectal are known as Gastrointestinal NETs.

Some of the key facts of the Neuroendocrine Tumor Market Report: 

• The Neuroendocrine Tumors market size is estimated to grow at a significant CAGR during the forecasted period (2019-2032) 
• It is estimated that more than 12,000 people in the United States are diagnosed with a Neuroendocrine Tumors each year 
• Key Neuroendocrine Tumor Companies: ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, and others 
• Key Neuroendocrine Tumor Therapies: 177Lu-edotreotide PRRT, CAM2029, Surufatinib, and others 

Get a Free sample for the Neuroendocrine Tumor Market Report:

https://www.delveinsight.com/report-store/neuroendocrine-tumors-market

Key benefits of the Neuroendocrine Tumor Market report:

1. Neuroendocrine Tumor market report covers a descriptive overview and comprehensive insight of the Neuroendocrine Tumor Epidemiology and Neuroendocrine Tumor market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Neuroendocrine Tumor market report provides insights on the current and emerging therapies.
3. Neuroendocrine Tumor market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Neuroendocrine Tumor market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Neuroendocrine Tumor market.

Download the report to understand which factors are driving Neuroendocrine Tumor epidemiology trends @ Neuroendocrine Tumor Epidemiological Insights

Neuroendocrine Tumor Market  

The dynamics of the Neuroendocrine Tumor market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

Neuroendocrine Tumor Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neuroendocrine Tumor Epidemiology Segmentation:

The Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Neuroendocrine Tumor
• Prevalent Cases of Neuroendocrine Tumor by severity
• Gender-specific Prevalence of Neuroendocrine Tumor
• Diagnosed Cases of Episodic and Chronic Neuroendocrine Tumor

Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Neuroendocrine Tumor treatment, visit @ Neuroendocrine Tumor Medications

Neuroendocrine Tumor Therapies and Key Companies

• 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen
• CAM2029: Camurus AB
• Surufatinib: Hutchison Medipharma Limited

Neuroendocrine Tumor Market Drivers

• Radiation therapy (RT) is a frequently used modality for cancer treatment. As a result, a huge population suffers from RD, which presents a huge market to any new entrant. 
• The diagnosis of the disorder is easy with a clear clinical presentation, which helps in identifying the disease

Neuroendocrine Tumor Market Unmet Needs

• Challenges in diagnoses
• Development of novel therapies
• Limitations in gene therapy
• Poor disease understanding
• Clinical biomarkers

Scope of the Neuroendocrine Tumor Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neuroendocrine Tumor Companies: ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, and others
• Key Neuroendocrine Tumor Therapies: 177Lu-edotreotide PRRT, CAM2029, Surufatinib, and others
• Neuroendocrine Tumor Therapeutic Assessment: Neuroendocrine Tumor current marketed and Neuroendocrine Tumor emerging therapies
• Neuroendocrine Tumor Market Dynamics: Neuroendocrine Tumor market drivers and Neuroendocrine Tumor market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Neuroendocrine Tumor Unmet Needs, KOL’s views, Analyst’s views, Neuroendocrine Tumor Market Access and Reimbursement 

Discover more about therapies set to grab major Neuroendocrine Tumor market share @ Neuroendocrine Tumor market forecast

Table of Contents 

1. Neuroendocrine Tumor Market Report Introduction

2. Executive Summary for Neuroendocrine Tumor

3. SWOT analysis of Neuroendocrine Tumor

4. Neuroendocrine Tumor Patient Share (%) Overview at a Glance

5. Neuroendocrine Tumor Market Overview at a Glance

6. Neuroendocrine Tumor Disease Background and Overview

7. Neuroendocrine Tumor Epidemiology and Patient Population

8. Country-Specific Patient Population of Neuroendocrine Tumor 

9. Neuroendocrine Tumor Current Treatment and Medical Practices

10. Neuroendocrine Tumor Unmet Needs

11. Neuroendocrine Tumor Emerging Therapies

12. Neuroendocrine Tumor Market Outlook

13. Country-Wise Neuroendocrine Tumor Market Analysis (2019–2032)

14. Neuroendocrine Tumor Market Access and Reimbursement of Therapies

15. Neuroendocrine Tumor Market Drivers

16. Neuroendocrine Tumor Market Barriers

17.  Neuroendocrine Tumor Appendix

18. Neuroendocrine Tumor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuroendocrine Tumor Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma

“CRISPR Therapies Pipeline”

“CRISPR therapies Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR therapies Market. 

The CRISPR therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

To know more about the CRISPR therapies pipeline report, click here: CRISPR therapies Pipeline Insight

Some facts of the CRISPR therapies pipeline report are:

• CRISPR therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR therapies treatment therapies, analyses DelveInsight
• Leading CRISPR therapies companies working in the market are Intellia Therapeutics, CRISPR therapeutics, Vertex Pharmaceuticals, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics, KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics, Graphite Bio, Nuntius Therapeutics and many others.
• Promising CRISPR therapies include CTX001, EDIT-101, CRISPR-based ex vivo cell therapy exagamglogene autotemcel (exa-cel) and others.

CRISPR Overview:

CRISPRs, short for “clusters of regularly interspaced short palindromic repeats,” are specialized segments of DNA distinguished by two primary features: repeated sequences of nucleotides, the building blocks of DNA, dispersed throughout the CRISPR region, and interspersed bits of DNA called spacers. These spacers within CRISPRs function in bacterial immunity regulation by retaining memories of previously encountered viruses. When bacteria encounter viruses, they incorporate snippets of viral DNA into their CRISPR arrays, creating a memory bank that aids in identifying and defending against future viral attacks. The revolutionary CRISPR/Cas9 gene-editing tool, stemming from this bacterial defense mechanism, has transformed biomedical research. Its potential in clinical trials signals a new era in CRISPR gene therapy, offering promising avenues for groundbreaking medical advancements.

Download Sample PDF Report to know in detail about the CRISPR therapies clinical trials and advancements @ https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight

DelveInsight’s CRISPR therapies Report covers around 30+ CRISPR products under different phases of clinical development like

• Late-stage CRISPR products (Phase III)
• Mid-stage CRISPR products (Phase II)
• Early-stage CRISPR product (Phase I)
• CRISPR Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• CRISPR Route of Administration

Emerging CRISPR therapies Under Different Phases of Clinical Development Include:

• CTX001: CRISPR Therapeutics
• EDIT-101: Editas Medicine
• And Many Others.

Further CRISPR therapies product details are provided in the report. Download the CRISPR report to learn more about the emerging CRISPR therapies at: https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight

CRISPR therapies Pipeline Analysis

The CRISPR therapies report provides insights into: 

• The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR therapies with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the CRISPR therapies Treatment.
• CRISPR therapies key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• CRISPR therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the CRISPR therapies market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report for CRISPR therapies pipeline assessment- https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight

Key companies in the CRISPR therapies Therapeutics Market:

Some of the CRISPR companies working in the market are Intellia Therapeutics, CRISPR therapeutics, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics,KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics,Graphite Bio, Nuntius Therapeutics.

Request for Sample PDF Report to know more about the CRISPR therapies and drugs by clicking here @ CRISPR therapies drugs and medication: https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. CRISPR therapies Current Treatment Patterns

4. CRISPR therapies – DelveInsight’s Analytical Perspective

5. CRISPR Therapeutic Assessment

6.  CRISPR therapies Late Stage Products (Phase-III)

7.  CRISPR therapies Mid-Stage Products (Phase-II)

8.  CRISPR therapies Early Stage Products (Phase-I)

9. CRISPR Pre-clinical Products and Discovery Stage Products

10. Inactive CRISPR Products

11. Dormant CRISPR Products

12.  CRISPR therapies Discontinued Products

13.  CRISPR therapies Product Profiles

14. Key Companies in the CRISPR therapies Market

15. Key Products in the CRISPR therapies Therapeutics Segment

16. Dormant and Discontinued Products

17. CRISPR therapies Unmet Needs

18. CRISPR therapies Future Perspectives

19. CRISPR therapies Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CRISPR Therapies Pipeline Report: FDA Approvals, Treatments, Clinical Trials, Companies by DelveInsight | Intellia Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, AstraZeneca, Novartis

“Knee Osteoarthritis Market”

DelveInsight’s “Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Knee Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Knee Osteoarthritis Market Forecast

Some of the key facts of the Knee Osteoarthritis Market Report: 

• The Knee Osteoarthritis market size was valued approximately USD 13 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Anticipated launch of potential Knee Osteoarthritis therapies by notable companies, including Techfields (X0002), Taiwan Liposome Company (TLC599), Centrexion Therapeutics (CNTX-4975), Biosplice Therapeutics (Lorecivivint), Ampio Pharmaceuticals (Ampion), Paradigm Biopharmaceuticals (Zilosul), Grünenthal (RTX-GRT7039/Resiniferatoxin), Naturecell (JointStem), and other contenders, might contribute to the market’s expansion of Knee Osteoarthritis in the upcoming years, supported by an expected rise in the prevalent population suffering from knee osteoarthritis.
• In 2021, the total prevalent population diagnosed with symptomatic Knee Osteoarthritis across the seven major markets reached 47,874,567. The United States reported the highest prevalence with 17,660,391 cases, while the combined cases in EU4 and the UK accounted for 19,946,245 cases.
• According to the assessment, a greater proportion of mild cases of knee Osteoarthritis was identified across the 7 Major Markets (7MM) in 2021, followed by moderate knee Osteoarthritis. In the United States specifically, the highest number of cases in 2021 was reported for mild knee osteoarthritis, with 7,373,858 cases, followed by moderate Knee Osteoarthritis, totaling 6,562,734 cases
• In the European Union (EU4) and the United Kingdom (UK) in 2021, the most significant percentage of cases was observed in the age group of 70 years and above, followed by the age categories of 60–69 years and 50–59 years. Specifically, there were 638,280, 1,735,323, 4,328,335, 4,807,045, and 8,437,262 cases documented in the age groups of 18–39 years, 40–49 years, 50–59 years, 60–69 years, and 70 years and above, respectively.
• Key Knee Osteoarthritis Companies: Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others
• Key Knee Osteoarthritis Therapies: TP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others
• The Knee Osteoarthritis epidemiology based on gender analyzed that females are most commonly affected than males in case of Knee Osteoarthritis
• The Knee Osteoarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Knee Osteoarthritis pipeline products will significantly revolutionize the Knee Osteoarthritis market dynamics.

Knee Osteoarthritis Overview

Degenerative joint disease, commonly referred to as osteoarthritis of the knee, is usually caused by articular cartilage gradually losing its structure due to wear and tear. It can be separated into two categories, main and secondary, and is most prevalent in the elderly.

Get a Free sample for the Knee Osteoarthritis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/knee-osteoarthritis-market

Knee Osteoarthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Knee Osteoarthritis Epidemiology Segmentation:

The Knee Osteoarthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Knee Osteoarthritis
• Prevalent Cases of Knee Osteoarthritis by severity
• Gender-specific Prevalence of Knee Osteoarthritis
• Diagnosed Cases of Episodic and Chronic Knee Osteoarthritis

Download the report to understand which factors are driving Knee Osteoarthritis epidemiology trends @ Knee Osteoarthritis Epidemiology Forecast

Knee Osteoarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Knee Osteoarthritis market or expected to get launched during the study period. The analysis covers Knee Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Knee Osteoarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Knee Osteoarthritis Therapies and Key Companies

• Retatrutide: Eli Lilly and Company
• JointStem: Nature Cell Co. Ltd.
• Semaglutide: Novo Nordisk A/S
• FX201: Flexion Therapeutics, Inc.
• RTX-GRT7039: Grünenthal GmbH
• TTAX03: Tissue Tech Inc.
• TG-C: Kolon TissueGene, Inc.
• SL-1002: Saol Therapeutics Inc
• PTP-001: Bioventus LLC
• StroMel: Akan Biosciences, LLC
• GNSC-001: Genascence Corporation
• IMM01-STEM: Immunis, Inc.
• RHH646: Novartis
• Lorecivivint: Biosplice Therapeutics
• Resiniferatoxin: Sorrento Therapeutics, Inc.
• DFV890: Novartis
• Celltex- AdMSCs: Celltex Therapeutics Corporation
• Micronized DHACM: MiMedx Group, Inc./Rho, Inc.
• X0002: Techfields Pharma Co. Ltd
• CNTX-4975: Centrexion Therapeutics
• TLC599: Taiwan Liposome Company
• Amniofix: MiMedx
• Ampion: Ampio Pharmaceuticals
• Organogenesis: ReNu
• Cartistem: Medipost

Discover more about therapies set to grab major Knee Osteoarthritis market share @ Knee Osteoarthritis Treatment Landscape

Knee Osteoarthritis Market Strengths

• Now companies are investing heavily in developing disease modifying therapies for the treatment of knee osteoarthritis, which will fulfill a major unmet need.
• Many key players are developing cell therapies for knee osteoarthritis, which are in various stages of development. These therapies, if approved, may provide better treatment options as it can slow disease progression and may possibly cure the disease.

Knee Osteoarthritis Market Opportunities

For the treatment of Knee OA, usage of opioids can be seen. The majority of patients/ physicians are eagerly waiting for nonopioids options and key players can target this lucrative segment of the market, while others are already developing therapies for the same.

Scope of the Knee Osteoarthritis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Knee Osteoarthritis Companies: Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others
• Key Knee Osteoarthritis Therapies: TP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others
• Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
• Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Knee Osteoarthritis Unmet Needs, KOL’s views, Analyst’s views, Knee Osteoarthritis Market Access and Reimbursement 

To know more about Knee Osteoarthritis companies working in the treatment market, visit @ Knee Osteoarthritis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Knee Osteoarthritis Market Report Introduction

2. Executive Summary for Knee Osteoarthritis

3. SWOT analysis of Knee Osteoarthritis

4. Knee Osteoarthritis Patient Share (%) Overview at a Glance

5. Knee Osteoarthritis Market Overview at a Glance

6. Knee Osteoarthritis Disease Background and Overview

7. Knee Osteoarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Knee Osteoarthritis 

9. Knee Osteoarthritis Current Treatment and Medical Practices

10. Knee Osteoarthritis Unmet Needs

11. Knee Osteoarthritis Emerging Therapies

12. Knee Osteoarthritis Market Outlook

13. Country-Wise Knee Osteoarthritis Market Analysis (2019–2032)

14. Knee Osteoarthritis Market Access and Reimbursement of Therapies

15. Knee Osteoarthritis Market Drivers

16. Knee Osteoarthritis Market Barriers

17.  Knee Osteoarthritis Appendix

18. Knee Osteoarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Knee Osteoarthritis Market is Expected to Grow at a Robust CAGR During the Forecast Period (2023-2032), States DelveInsight | Novartis, Biosplice Therapeutic, Sorrento Therapeutic, Eli Lilly

“Non-Hodgkin Lymphoma Pipeline”

As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Non-Hodgkin Lymphoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma Market.

Some of the key takeaways from the Non-Hodgkin Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years. 
• Non-Hodgkin Lymphoma companies working in the treatment market are Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others, are developing therapies for the Non-Hodgkin Lymphoma treatment 

• Emerging Non-Hodgkin Lymphoma therapies in the different phases of clinical trials are- AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others are expected to have a significant impact on the Non-Hodgkin Lymphoma market in the coming years.   
• In May 2023, The US FDA has granted approval for the investigational new drug (IND) application submitted by SIRPant Immuno therapeutics. This approval allows the commencement of a phase I clinical trial, marking the first time the treatment will be tested in humans, aimed at addressing relapsed refractory non-Hodgkin lymphoma.
• In May 2023, The US FDA has granted approval to AbbVie for EPKINLY (epcoritamab-bysp), a T-cell engaging bispecific antibody designed for treating adult patients experiencing relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Non-Hodgkin Lymphoma Overview

A malignancy of the lymphatic system is called non-Hodgkin’s lymphoma (NHL). It happens when lymphocytes give rise to tumors. One variety of white blood cell is the lymphocyte. NHL is more prevalent than lymphoma Hodgkin’s. The presence of a particular kind of aberrant cell known as the Reed-Sternberg cell is the primary distinction between NHL and Hodgkin’s lymphoma.

Get a Free Sample PDF Report to know more about Non-Hodgkin Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight 

Emerging Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:

• AUTO4: Autolus
• GB226: Genor Biopharma
• Epcoritamab: AbbVie/ Genmab
• Capivasertib: AstraZeneca
• HRS-3738: Jiangsu Hengrui Medicine
• PCLX-001: Pacylex Pharmaceuticals
• ZN-d5: Zentera Therapeutics
• TC-110: TCR2 Therapeutics
• AB-101: Artiva Biotherapeutics
• LOXO-305: Loxo Oncology
• AB-205: Angiocrine Bioscience
• Venetoclax: AbbVie
• Tisagenlecleucel: Novartis 

Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment

• Non-Hodgkin Lymphoma Assessment by Product Type
• Non-Hodgkin Lymphoma By Stage and Product Type
• Non-Hodgkin Lymphoma Assessment by Route of Administration
• Non-Hodgkin Lymphoma By Stage and Route of Administration
• Non-Hodgkin Lymphoma Assessment by Molecule Type
• Non-Hodgkin Lymphoma by Stage and Molecule Type

DelveInsight’s Non-Hodgkin Lymphoma Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Hodgkin Lymphoma product details are provided in the report. Download the Non-Hodgkin Lymphoma pipeline report to learn more about the emerging Non-Hodgkin Lymphoma therapies

Some of the key companies in the Non-Hodgkin Lymphoma Therapeutics Market include:

Key companies developing therapies for Non-Hodgkin Lymphoma are – AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, and others.

Non-Hodgkin Lymphoma Pipeline Analysis:

The Non-Hodgkin Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.
• Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Hodgkin Lymphoma drugs and therapies

Non-Hodgkin Lymphoma Pipeline Market Drivers

• Increasing prevalence, ongoing and increased R&D activity, demand for innovative drugs and novel therapies are some of the important factors that are fueling the Non-Hodgkin Lymphoma Market.

Non-Hodgkin Lymphoma Pipeline Market Barriers

• However, high cost of treatment, complications related to the drugs and other factors are creating obstacles in the Non-Hodgkin Lymphoma Market growth.

Scope of Non-Hodgkin Lymphoma Pipeline Drug Insight    

• Coverage: Global
• Key Non-Hodgkin Lymphoma Companies: Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others
• Key Non-Hodgkin Lymphoma Therapies: AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others
• Non-Hodgkin Lymphoma Therapeutic Assessment: Non-Hodgkin Lymphoma current marketed and Non-Hodgkin Lymphoma emerging therapies
• Non-Hodgkin Lymphoma Market Dynamics: Non-Hodgkin Lymphoma market drivers and Non-Hodgkin Lymphoma market barriers 

Request for Sample PDF Report for Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. Non-Hodgkin Lymphoma Report Introduction

2. Non-Hodgkin Lymphoma Executive Summary

3. Non-Hodgkin Lymphoma Overview

4. Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Non-Hodgkin Lymphoma Pipeline Therapeutics

6. Non-Hodgkin Lymphoma Late Stage Products (Phase II/III)

7. Non-Hodgkin Lymphoma Mid Stage Products (Phase II)

8. Non-Hodgkin Lymphoma Early Stage Products (Phase I)

9. Non-Hodgkin Lymphoma Preclinical Stage Products

10. Non-Hodgkin Lymphoma Therapeutics Assessment

11. Non-Hodgkin Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Hodgkin Lymphoma Key Companies

14. Non-Hodgkin Lymphoma Key Products

15. Non-Hodgkin Lymphoma Unmet Needs

16 . Non-Hodgkin Lymphoma Market Drivers and Barriers

17. Non-Hodgkin Lymphoma Future Perspectives and Conclusion

18. Non-Hodgkin Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Hodgkin Lymphoma Pipeline Assessment 2024: FDA Approvals, Therapies, Clinical Trials and Key Companies involved by DelveInsight | AstraZeneca, Baxter, Bayer, Bristol Myers Squibb, Teva Pharma